Lifecore Biomedical (NASDAQ: LFCR) reported Q3 fiscal 2025 financial results with revenues of $35.2 million, down 2% from $35.7 million in the prior year period. The company recorded a net loss of $14.8 million ($0.47 per share) compared to net income of $15.6 million in Q3 2024.
Key developments include:Multiple new development agreements signed with new and existing customers
Sale of unused filler equipment for $17 million, strengthening balance sheet
Adjusted EBITDA of $5.7 million, down from $6.4 million year-over-year
Gross profit decreased to $9.8 million from $11.9 million
The company maintained its fiscal 2025 guidance, expecting revenue of $126.5-130 million and Adjusted EBITDA of $19-21 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.